pSivida Corp. develops tiny, sustained release, drug delivery products designed to deliver medicine at a controlled and steady rate for months or years. The company is presently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert and BioSilicon. One of the company’s offerings is the FDA-approved Retisert, which is licensed to Bausch & Lomb and provides long-term, sustained drug delivery to treat posterior uveitis, a chronic back-of-the-eye disease. For more information, visit the company’s website at www.psivida.com.